Abstract:Background: Stroke is a common neurological disorder that disproportionately affects middle-aged and elderly individuals, leading to significant disability and mortality. Recently, human blood metabolites have been discovered to be useful in unraveling the underlying biological mechanisms of neurological disorders. Therefore, we aimed to evaluate the causal relationship between human blood metabolites and susceptibility to stroke. Methods: Summary data from genome-wide association studies (GWASs) of serum metabolites and stroke and its subtypes were obtained separately. A total of 486 serum metabolites were used as the exposure. Simultaneously, 11 different stroke phenotypes were set as the outcomes, including any stroke (AS), any ischemic stroke (AIS), large artery stroke (LAS), cardioembolic stroke (CES), small vessel stroke (SVS), lacunar stroke (LS), white matter hyperintensities (WMH), intracerebral hemorrhage (ICH), subarachnoid hemorrhage (SAH), transient ischemic attack (TIA), and brain microbleeds (BMB). A two-sample Mendelian randomization (MR) study was conducted to investigate the causal effects of serum metabolites on stroke and its subtypes. The inverse variance-weighted MR analyses were conducted as causal estimates, accompanied by a series of sensitivity analyses to evaluate the robustness of the results. Furthermore, a reverse MR analysis was conducted to assess the potential for reverse causation. Additionally, metabolic pathway analysis was performed using the web-based MetOrigin. Results: After correcting for the false discovery rate (FDR), MR analysis results revealed remarkable causative associations with 25 metabolites. Further sensitivity analyses confirmed that only four causative associations involving three specific metabolites passed all sensitivity tests, namely ADpSGEGDFXAEGGGVR* for AS (OR: 1.599, 95% CI 1.283-1.993, p = 2.92 × 10-5) and AIS (OR: 1.776, 95% CI 1.380-2.285, p = 8.05 × 10-6), 1-linoleoylglycerophosph-oethanolamine* for LAS (OR: 0.198, 95% CI 0.091-0.428, p = 3.92 × 10-5), and gamma-glutamylmethionine* for SAH (OR: 3.251, 95% CI 1.876-5.635, p = 2.66 × 10-5), thereby demonstrating a high degree of stability. Moreover, eight causative associations involving seven other metabolites passed both sensitivity tests and were considered robust. The association result of one metabolite (glutamate for LAS) was considered non-robust. As for the remaining metabolites, we speculate that they may potentially possess underlying causal relationships. Notably, no common metabolites emerged from the reverse MR analysis. Moreover, after FDR correction, metabolic pathway analysis identified 40 significant pathways across 11 stroke phenotypes. Conclusions: The identified metabolites and their associated metabolic pathways are promising circulating metabolic biomarkers, holding potential for their application in stroke screening and preventive strategies within clinical settings.

Causal relationship between metabolites and embolic stroke: based on Mendelian randomization and metabolomics

Metabolite Associations with Childhood and Juvenile Absence Epilepsy: A Bidirectional Mendelian Randomization Study

Causal effects of human serum metabolites on occurrence and progress indicators of chronic kidney disease: a two-sample Mendelian randomization study

Causal relationship between human blood metabolites and risk of ischemic stroke: a Mendelian randomization study

Assessing the causal effect of genetically predicted metabolites and metabolic pathways on stroke

Exploring the causal association between genetically determined circulating metabolome and hemorrhagic stroke.

Association of metabolites on ischemic stroke subtypes: a 2-sample Mendelian randomization study

Causality of blood metabolites and metabolic pathways on peripheral arteriosclerosis: a Mendelian randomization study

The causal relationship between 233 metabolites and coronary atherosclerosis: a Mendelian randomization study

Causal relationship between genetically determined plasma metabolites and stroke: A two sample Mendelian randomization study

Genetic determinants of circulating metabolites and the risk of stroke and its subtypes

Causal association between blood metabolites and risk of hypertension: a Mendelian randomization study

Related factors with vascular dementia: A Two-Sample Mendelian Randomization Study

Dissecting Causal Relationships Between Gut Microbiota, Blood Metabolites, and Stroke: A Mendelian Randomization Study

Circulating metabolites and coronary heart disease: a bidirectional Mendelian randomization

Assessing the causal relationship between metabolic biomarkers and coronary artery disease by Mendelian randomization studies

Association between human blood metabolome and the risk of coronary heart disease: Mendelian randomization study

Causal Relations Between Exposome and Stroke: A Mendelian Randomization Study.

Pulmonary embolism and 529 human blood metabolites: genetic correlation and two-sample Mendelian randomization study

Genetic Insights into the Risk of Metabolic Syndrome and Its Components on Stroke and Its Subtypes: Bidirectional Mendelian Randomization.

Causal association between 1400 metabolites and dilated cardiomyopathy: a bidirectional two-sample Mendelian randomization analysis